Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Holtbäck U and Eklöf AC | Mechanism of FK 506/520 action on rat renal proximal tubular Na+, K+-ATPase activity. | 1999 | Kidney Int. | pmid:10469369 |
Grassberger M et al. | A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. | 1999 | Br. J. Dermatol. | pmid:10468798 |
Yokogawa K et al. | P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. | 1999 | Pharm. Res. | pmid:10468022 |
Ogino Y et al. | Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats. | 1999 | J. Pharm. Pharmacol. | pmid:10467956 |
Johnson CE and Truong NM | Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride. | 1999 Jul-Aug | J Am Pharm Assoc (Wash) | pmid:10467814 |
Ivery MT | A proposed molecular model for the interaction of calcineurin with the cyclosporin A-cyclophilin A complex. | 1999 | Bioorg. Med. Chem. | pmid:10465413 |
Shuto H et al. | Inhibition of GABA system involved in cyclosporine-induced convulsions. | 1999 | Life Sci. | pmid:10465348 |
Alexanian AR and Bamburg JR | Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. | 1999 | FASEB J. | pmid:10463953 |
Wandel C et al. | P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. | 1999 | Cancer Res. | pmid:10463589 |
Arndt C et al. | Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. | 1999 | Microbiology (Reading, Engl.) | pmid:10463165 |